{"id":"W3046033709","doi":"10.1177/2047487320941987","title":"Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial","year":2020,"lang":"en","type":"article","venue":"European Journal of Preventive Cardiology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta; St. Michael's Hospital","funders":"Genentech; Esperion Therapeutics; Sirtex Medical; Servier; Eisai; Medicines Company; Amarin Corporation; Regeneron Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; European Society of Cardiology; American Regent; Sanofi; Amgen; Pfizer","keywords":"Alirocumab; Medicine; Statin; Internal medicine; Hazard ratio; PCSK9; Acute coronary syndrome; Adverse effect; Placebo; Myocardial infarction; Cardiology; Cholesterol; Confidence interval; Lipoprotein; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007634363,0.0001717201,0.000925719,0.00003722264,0.00005996049,0.000007909244,0.000115009,0.00004342831,0.00001396802],"category_scores_gemma":[0.0002856495,0.0000982324,0.0004218013,0.00006626068,0.00009807666,0.00006813486,0.00007256116,0.0003000788,0.000007962063],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004747212,"about_ca_system_score_gemma":0.00008358601,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002783905,"about_ca_topic_score_gemma":0.000001403509,"domain_scores_codex":[0.9962223,0.002524471,0.000621068,0.0002271318,0.0002707659,0.0001343129],"domain_scores_gemma":[0.9986596,0.0001527015,0.0005204329,0.000245605,0.0002570528,0.0001646341],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3199832,0.001665735,0.3642952,0.0003366104,0.08594306,0.02940043,0.03087184,0.0001585736,0.02665458,0.0001567333,0.01977203,0.120762],"study_design_scores_gemma":[0.02350681,0.00609544,0.9641715,0.00006459963,0.002020378,0.0005995285,0.0004239169,0.000008504938,0.0005645397,0.00005572785,0.00238328,0.0001057634],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894409,0.007451671,0.001014459,0.0009780109,0.0002044724,0.0006374533,0.0001731088,0.000007228279,0.00009267147],"genre_scores_gemma":[0.9965653,0.002461701,0.0002057584,0.0003225821,0.0003348858,0.000006313402,0.00003330793,0.00002227701,0.00004789265],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5998763,"threshold_uncertainty_score":0.4005801,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02869394666617581,"score_gpt":0.2715843761862793,"score_spread":0.2428904295201035,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}